Apimeds Pharmaceuticals US, Inc.
APUS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for APUS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APUS
Apimeds Pharmaceuticals US, Inc. (APUS) is a development-stage biopharmaceutical company focused on advancing its lead product candidate, Apitox, through clinical development, with no product revenues to date and a history of operating losses.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Apimeds Pharmaceuticals US, Inc..
Apimeds Pharmaceuticals US, Inc. (APUS) is a development-stage biopharmaceutical company focused on advancing its lead product candidate, Apitox, through clinical development, with no product revenues to date and a history of operating losses.
- Apimeds operates through two reportable segments, including a BioBusiness segment conducted through subsidiary Lokahi Therapeutics Inc. [sec_mda · as of 2026-08-14]
- The company has not generated any product revenues to date and does not expect significant revenues until regulatory approval or collaboration funding is secured [sec · filed 2024-09-25]
- As of June 30, 2026, Apimeds reported cash & equivalents of $8.3M, net income of -$20.2M, shareholders' equity of $9.7M, and total debt of $5.0M [sec]
- The company reported a net loss of $6.0 million and used $8.9 million in cash in operating activities for the year ended December 31, 2025, with an accumulated deficit of $10.3 million [sec_mda · as of 2026-05-04]
- Management has expressed substantial doubt about the company's ability to continue as a going concern, with existing cash as of December 31, 2024 not sufficient for 12 months of operating needs [sec_mda · as of 2026-05-04][sec_mda · as of 2025-04-15]
What works
- The company has a Securities Purchase Agreement providing for the issuance of up to $129.0 million in aggregate principal to address near-term liquidity needs [sec_mda · as of 2026-05-04]
- Apimeds is advancing Apitox through clinical development, which represents a potential future revenue source if regulatory approval is obtained [sec_mda · as of 2026-05-04]
What to weigh
- The company has no product revenues and expects to continue incurring significant operating losses as it advances clinical development and builds operational infrastructure [sec_mda · as of 2026-05-04]
- Substantial doubt exists about the company's ability to continue as a going concern, with existing cash insufficient to cover 12 months of operating needs [sec_mda · as of 2026-05-04][sec_mda · as of 2025-04-15]
- Significant manufacturing costs related to Apitox development are expected beginning in the first quarter of 2026 and throughout the year, increasing cash burn [sec_mda · as of 2026-05-04]
- The company faces risks of delays, reductions, or eliminations of research programs if unable to obtain additional funding [sec · filed 2024-09-25]
From the filings
Quoted directly from source documents.
The company has not generated product revenues and is dependent on funding for operations
“We are a development stage company as we have not generated any product revenues to date and do not expect to have significant revenues until we are able to sell a product candidate after obtaining applicable regulatory approvals or we establish collaborations that provide funding”
SEC filings · September 25, 2024
Substantial doubt about going concern due to insufficient cash
“These conditions raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · May 4, 2026
Net loss and cash used in operations for 2025
“we reported a net loss of $6.0 million and used $8.9 million in cash in operating activities. As of December 31, 2025, our accumulated deficit was $10.3 million.”
SEC MD&A · May 4, 2026
Liquidity plan includes Securities Purchase Agreement
“Management's primary plan to address near-term liquidity needs is the continued execution of additional tranches under the Securities Purchase Agreement, which provides for the issuance of up to $129.0 million in aggregate principal”
SEC MD&A · May 4, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern; existing cash insufficient for 12 months of operations [sec_mda · as of 2026-05-04][sec_mda · as of 2025-04-15]
- No product revenue — No product revenues to date; significant operating losses expected to continue [sec · filed 2024-09-25][sec_mda · as of 2026-05-04]
- Manufacturing cost burden — Significant manufacturing costs for Apitox expected from Q1 2026 onward, increasing cash burn [sec_mda · as of 2026-05-04]
- Funding dependency — If unable to obtain funding, may delay, reduce, or eliminate R&D programs [sec · filed 2024-09-25]
What to watch
- Execution of additional tranches under the Securities Purchase Agreement to secure near-term liquidity [sec_mda · as of 2026-05-04]
- Progress and costs of Apitox clinical development and manufacturing [sec_mda · as of 2026-05-04]
- Ability to achieve regulatory approval for Apitox and generate product revenue [sec · filed 2024-09-25]
- Cash runway and potential need for additional financing given accumulated deficit and operating losses [sec_mda · as of 2026-05-04]
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Apimeds Pharmaceuticals US, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Apimeds Pharmaceuticals US, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
4.8 months
D/E 0.20 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$967K
| Holder | Shares | Value |
|---|---|---|
| hemenway trust co llc | 274,000 | $490K |
| vanguard capital management llc | 191,858 | $343K |
| geode capital management, llc | 40,051 | $72K |
| vanguard fiduciary trust co | 24,039 | $43K |
| two sigma securities, llc | 10,550 | $19K |
Short Interest
as of May 20, 2026- % of float
- 1.7%
- Days to cover
- 21.1
- Shares short
- 92,972
- Daily short volume (Jul 6, 2026)
- 46.6%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APUS short interestFrequently asked questions
What is the AI investment thesis for Apimeds Pharmaceuticals US, Inc.?
Apimeds Pharmaceuticals US, Inc. (APUS) is a development-stage biopharmaceutical company focused on advancing its lead product candidate, Apitox, through clinical development, with no product revenues to date and a history of operating losses.
What is Apimeds Pharmaceuticals US, Inc.'s lead drug candidate?
Apimeds Pharmaceuticals US, Inc.'s most advanced tracked candidate is apitox (Preclinical) for Multiple Sclerosis (MS).
Who is the CEO of Apimeds Pharmaceuticals US, Inc.?
Dr. Vinod Menon is the chief executive officer of Apimeds Pharmaceuticals US, Inc. (APUS).
Where is Apimeds Pharmaceuticals US, Inc. headquartered?
Apimeds Pharmaceuticals US, Inc. (APUS) is headquartered in Matawan, NJ, United States.
What therapeutic areas does Apimeds Pharmaceuticals US, Inc. focus on?
Apimeds Pharmaceuticals US, Inc. develops therapies across Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.